Table 3.
Adverse events occurrence over 12 months after the index date (patients with at least 12 months of follow-up after ADA or IFX treatment initiation)
| IFX (n = 49) | ADA (n = 37) | Total (n = 86) | p value* | |
|---|---|---|---|---|
| Adverse events (at least one event), n (%) | 34 (69.4%) | 19 (51.4%) | 53 (61.6%) | 0.09 |
| Certain infectious and parasitic diseases, n (%) | 15 (30.6%) | 6 (16.2%) | 21 (24.4%) | 0.12 |
| Intestinal infectious diseases | 5 (10.2%) | 1 (2.7%) | 6 (7.0%) | 0.23 |
| Mycoses | 3 (6.1%) | 5 (13.5%) | 8 (9.3%) | 0.28 |
| Other infection | 8 (16.3%) | 0 | 8 (9.3%) | 0.01 |
| Anemia, n (%) | 10 (20.4%) | 8 (21.6%) | 18 (20.9%) | 0.89 |
| Diseases of the digestive system, n (%) | 3 (6.1%) | 1 (2.7%) | 4 (4.7%) | 0.63 |
| Diseases of the respiratory system, n (%) | 8 (16.3%) | 3 (8.1%) | 11 (12.8%) | 0.34 |
| Malignant neoplasms, n (%) | 0 | 1 (2.7%) | 1 (1.2%) | 0.43 |
| Other adverse events, n (%)a | 10 (20.4%) | 5 (13.5%) | 15 (17.4%) | 0.40 |
ADA adalimumab, IFX infliximab
* Continuous variables were compared using the student test or the Wilcoxon test; categorical variables were compared using the Chi-square test or the Fisher’s exact test
aList of other adverse events: Endocrine, nutritional and metabolic diseases, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, symptoms, signs and abnormal clinical and laboratory findings, injury, poisoning, and certain other consequences of external causes